Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity

被引:56
作者
Grabb, PA
Guin-Renfroe, S
Meythaler, JM
机构
[1] Childrens Hosp, Birmingham, AL 35233 USA
[2] Univ Alabama, Dept Surg, Div Neurosurg, Birmingham, AL 35294 USA
[3] Univ Alabama, Dept Rehabil Med, Birmingham, AL 35294 USA
关键词
baclofen; intrathecal; spasticity; technique;
D O I
10.1097/00006123-199910000-00020
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: In an effort to increase the effect of intrathecal baclofen on upper-extremity spasticity, the tip of the intrathecal catheter was placed at the T6-T7 level rather than at the traditional T11-T12 level in children with spastic quadriparesis. METHODS: Twelve children with spastic quadriparesis from varying causes had significant reductions in spasticity after a test dose of intrathecal baclofen and subsequently underwent placement of a programmable pump and intrathecal catheter tip placed at the T6-T7 level with fluoroscopic guidance. With the use of Ashworth scores for four muscle groups in both the upper and lower extremities, degrees of spasticity were determined by a physiatrist preoperatively and at 1, 3, 6, and 12 months postoperatively. Mean changes in upper- and lower-extremity Ashworth scores and baclofen dosages for the entire cohort were compared with published results in which the catheter tip had been placed at the T11-T12 level. RESULTS: Spasticity was significantly reduced in all muscle groups (P < 0.001). The lower-extremity reduction in spasticity of 1.6 points at 3 and 12 months was greater than published reductions of 1.1 points at 3 and 12 months. The upper-extremity reduction in spasticity was noticeably greater at 3 and 12 months (1.7 and 2.0 points, respectively) than published results at 3 and 12 months (0.4 and 0.6 points, respectively). At 3, 6, and 12 months, our mean baclofen dosage remained below the dosages administered at the T11-T12 level. There were no complications related either to the positioning of the catheter higher in the spinal canal or to the administration of baclofen at the T6-T7 level. CONCLUSION: Compared with published results, placement of the tip of the intrathecal catheter at the T6-T7 level was associated with greater relief of upper-extremity spasticity without loss of effect on the lower extremities. The mean dosages of baclofen in our study group were lower compared with mean dosages administered at the T11-T12 level. There was no morbidity related to the more rostral location of the catheter.
引用
收藏
页码:833 / 836
页数:4
相关论文
共 6 条
[1]  
ALBRIGHT AL, 1995, PEDIATR NEUROSURG, V23, P82
[2]   CONTINUOUS INTRATHECAL BACLOFEN INFUSION FOR SPASTICITY OF CEREBRAL ORIGIN [J].
ALBRIGHT, AL ;
BARRON, WB ;
FASICK, MP ;
POLINKO, P ;
JANOSKY, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (20) :2475-2477
[3]   INTRATHECAL DRUG ADMINISTRATION - PRESENT USE AND FUTURE-TRENDS [J].
KROIN, JS .
CLINICAL PHARMACOKINETICS, 1992, 22 (05) :319-326
[4]  
KROIN JS, 1993, NEUROSURGERY, V33, P226
[5]   Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report [J].
Meythaler, JM ;
McCary, A ;
Hadley, MN .
JOURNAL OF NEUROSURGERY, 1997, 87 (03) :415-419
[6]   INTRATHECAL BACLOFEN FOR SPASTICITY OF SPINAL ORIGIN - 7 YEARS OF EXPERIENCE [J].
PENN, RD .
JOURNAL OF NEUROSURGERY, 1992, 77 (02) :236-240